Evaluating Treatment Effects with Patient-Response-Related Outcomes in Comparative Clinical Trials.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41288427.
- Also identified by DOI 10.1056/EVIDctw2400349.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
AbstractIn comparative clinical investigations for nearly all disease types, patient responses - signifying clinically meaningful improvements in health or reductions in disease burden - are routinely employed as key end points for assessing treatment activity or efficacy. Trials typically use the response rate to summarize treatment effects, a metric with limitations for investigating the temporal profile of the effect. In this Clinical Trials Workshop, the authors present a novel approach for analyzing time to response and duration of response in clinical trials using, as an example, data from the JAVELIN Renal-101 trial of avelumab and axitinib versus sunitinib for treating renal cell carcinoma.
Medical subject headings
- Kidney Neoplasms
- Carcinoma, Renal Cell
- Clinical Trials as Topic
- Antineoplastic Agents